MedTrace Logo

Descriptive Observational Study of Patient-performed Pre-oxygenation

NCT06361693 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2025-09-12

No results posted yet for this study

Summary

The aim of this research would be to determine the efficacy and effects of preoxygenation when performed by the patient (mask held by the patient).

This is the concept of "self-preoxygenation".

Conditions

  • Anesthesia
  • ASA Physical Status I
  • ASA Physical Status II

Interventions

OTHER

Auto-preoxygenation

Management is not modified. Routine monitoring (ECG, BP, SpO2). As in care, the patient takes the mask and the respirator is started, delivering an inspired oxygen fraction of 100% (FiO2=1). Monitoring of : inspired fraction of oxygen, expired fraction of oxygen and end-tidal fraction of carbon dioxide. The ventilator also provides the respiratory rate and tidal volume carried out by the patient. The fresh gas flow is set by default and will be adjusted to 12l/min for patient comfort.After less than a minute, a normal capnia curve and the presence of an FeO2 value appear. Here, time is standardized to 1 min. In the absence of one of these elements, the caregiver always takes control of preoxygenation.Timer is started, it is T0 min. At T 3min, collection of values and decision-making : * objectives achieved : end of this sequence. * objectives not achieved, the caregiver takes control again for an additional 2 minutes in order to seek to achieve an FeO2\>90%.

OTHER

APAIS scale

APAIS scale

OTHER

Visual analog anxiety scale (VAS-A)

Visual analog anxiety scale (VAS-A)

OTHER

Visual analog comfort scale (VAS-C)

Visual analog comfort scale (VAS-C)

Sponsors & Collaborators

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Sophie TOUSSAINT, Nurse anesthetist · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-14
Primary Completion
2024-10-30
Completion
2024-10-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06361693 on ClinicalTrials.gov